In contrast to batch operations run under constant pressure or high flux, virus filtration in continuous processes may be operated at very low flux, a condition which may reduce the viral retention performance of the filter. To overcome this limitation, two novel approaches are described. One uses intermittent high flux operation, and the other utilizes serial virus filtration, with a high area ratio between first to second stage filters. Theoretical and experimental case studies confirm that these methods provide robust virus retention performance, high filter productivity, and long filter changeout times for continuous processing applications.
In this webinar, you will learn:
- The benefits of transitioning from batch to continuous bioprocessing for enhanced productivity and process control
- Challenges associated with low flux operation in continuous virus filtration and its impact on viral retention
- Innovative operational strategies such as intermittent high flux and serial filtration to optimize virus filtration performance
- The advantages of using the Viresolve® Pro Device for higher virus retention and reduced filter fouling
- Practical insights for implementing these novel filtration techniques in biopharmaceutical manufacturing to improve efficiency and output
Speaker
Sal Giglia
Merck
Filtration Fellow
Sal Giglia is a filtration fellow at Merck with 40 years of experience in the area of membrane-based separations. He is listed as an inventor in more than 30 patents related to membrane separation devices and processes and has authored a number of publications covering various aspects of membrane filtration technology, including process modeling, sterile filtration, virus filtration, integrity testing and scalability. He received his B.S. in chemical engineering from Tufts University and M.S. in chemical engineering from the University of Massachusetts.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
期间:1h
语言:English
场次 1:往期 July 11, 2024
如要继续阅读，请登录或创建帐户。
暂无帐户？